title: Plasma and tissue proteomic prognostic factors of response in primary             breast cancer patients receiving neoadjuvant chemotherapy.
abstract: A pathological complete response (pCR) after neoadjuvant chemotherapy is             observed in approximately 20% of breast cancer patients. A proteomic analysis             was performed on plasma and tumor tissue before treatment to evaluate its potential             impact on the prediction of response. One hundred and forty-nine breast cancer             patients eligible for neoadjuvant chemotherapy were included in the study between             February 2004 and January 2009 at three centers. The proteomic analysis was performed             using SELDI Technology (ProteinChip CM10 pH4, IMAC-Cu and H50). Three acquisition             protocols were used according to the mass range. Plasma and tumor proteomic signatures             were generated using generalized ROC criteria and cross-validation. Twenty-eight             (18.8%) patients out of 149 experienced a pCR according to Sataloff criteria.             In the cytosol analysis, respectively 4, 2 and 8 proteins had significantly different             levels of expression in the responders and non-responders using IMAC-Cu, H50 and             CM10 pH4. Among the 8 proteins of interest on CM10 pH4, 2 (C1 and C7) were selected             and were validated in 95.0 and 85.6% of the models. In the plasma analysis, respectively             12, 6 and 2 proteins had different levels of expression using the same proteinchips.             Among the 12 plasma proteins of interest on IMAC-Cu, 2 (P1 and P7) were selected             and were validated in 94.8 and 97.6% of the models. A combined proteomic signature             was generated, which remained statistically significant when adjusted for hormone             receptor status and Ki-67. Our results show that proteomic analysis can differentiate             complete pathological responders in breast cancer patients after neoadjuvant chemotherapy.
authors.affiliation: Oscar Lambret Center, Lille-North of France University, Regional University Hospital, F-59000 Lille, France. j-bonneterre@o-lambret.fr
authors.forename: J
authors.initials: J
authors.lastname: Bonneterre
authors.forename: F
authors.initials: F
authors.lastname: Révillion
authors.forename: C
authors.initials: C
authors.lastname: Desauw
authors.forename: E
authors.initials: E
authors.lastname: Blot
authors.forename: A
authors.initials: A
authors.lastname: Kramar
authors.forename: C
authors.initials: C
authors.lastname: Fournier
authors.forename: L
authors.initials: L
authors.lastname: Hornez
authors.forename: J P
authors.initials: JP
authors.lastname: Peyrat
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D040081:Protein Array Analysis; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D001798:Blood Proteins; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil